Skip to main content
NASDAQ:RETA

Reata Pharmaceuticals Stock Forecast, Price & News

$79.07
+0.80 (+1.02 %)
(As of 05/14/2021 02:40 PM ET)
Add
Compare
Today's Range
$76.35
$79.17
50-Day Range
$81.62
$103.79
52-Week Range
$77.48
$186.82
Volume8,617 shs
Average Volume306,788 shs
Market Capitalization$2.86 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.57
30 days | 90 days | 365 days | Advanced Chart
Receive RETA News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Reata Pharmaceuticals logo

About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RETA
CUSIPN/A
Phone972-865-2219
Employees261
Year FoundedN/A

Sales & Book Value

Annual Sales$26.52 million
Book Value$7.74 per share

Profitability

Net Income$-290,170,000.00
Net Margins-4,340.72%

Debt

Price-To-Earnings

Miscellaneous

Market Cap$2.86 billion
Next Earnings Date8/9/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.39 out of 5 stars

Medical Sector

715th out of 2,039 stocks

Pharmaceutical Preparations Industry

336th out of 769 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions

Is Reata Pharmaceuticals a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Reata Pharmaceuticals stock.
View analyst ratings for Reata Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Reata Pharmaceuticals?

Wall Street analysts have given Reata Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Reata Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Reata Pharmaceuticals' next earnings date?

Reata Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Reata Pharmaceuticals
.

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) posted its quarterly earnings data on Thursday, May, 6th. The company reported ($1.86) earnings per share for the quarter, topping analysts' consensus estimates of ($2.18) by $0.32. The firm had revenue of $0.94 million for the quarter, compared to the consensus estimate of $1.43 million. Reata Pharmaceuticals had a negative trailing twelve-month return on equity of 163.42% and a negative net margin of 4,340.72%. The firm's revenue was down 30.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.89) earnings per share.
View Reata Pharmaceuticals' earnings history
.

How has Reata Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Reata Pharmaceuticals' stock was trading at $157.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RETA shares have decreased by 50.4% and is now trading at $78.26.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RETA?

6 Wall Street analysts have issued 12 month target prices for Reata Pharmaceuticals' shares. Their forecasts range from $155.00 to $268.00. On average, they expect Reata Pharmaceuticals' stock price to reach $227.13 in the next year. This suggests a possible upside of 190.2% from the stock's current price.
View analysts' price targets for Reata Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Reata Pharmaceuticals' key executives?

Reata Pharmaceuticals' management team includes the following people:
  • Mr. J. Warren Huff, Chairman, CEO & Pres (Age 67, Pay $1.2M)
  • Mr. Manmeet Singh Soni, COO, CFO & Exec. VP (Age 43, Pay $1.01M)
  • Mr. Michael D. Wortley, Exec. VP & Chief Legal Officer (Age 73, Pay $724.2k)
  • Dr. Colin J. Meyer, Exec. VP and Chief R&D Officer (Age 42, Pay $835.07k)
  • Ms. Dawn Carter Bir, Exec. VP & Chief Commercial Officer (Age 50, Pay $666.15k)
  • Ms. Elaine Castellanos, VP & Chief Accounting Officer
  • Mr. Kevin A. Johnston, VP & Chief Technical Officer
  • Dr. W. Christian Wigley, Sr. VP, Chief Scientific Officer & Founding Scientist
  • Mr. Dakota Gallivan, VP & Chief Healthcare Compliance Officer
  • Ms. Claudia Bujold, VP of Marketing

What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?

10 employees have rated Reata Pharmaceuticals CEO Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among Reata Pharmaceuticals' employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Reata Pharmaceuticals' key competitors?

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an initial public offering (IPO) on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO.

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Who are Reata Pharmaceuticals' major shareholders?

Reata Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (4.10%), Franklin Resources Inc. (4.03%), Geode Capital Management LLC (0.93%), Emerald Advisers LLC (0.72%), Emerald Mutual Fund Advisers Trust (0.69%) and Northern Trust Corp (0.36%). Company insiders that own Reata Pharmaceuticals stock include Elaine Castellanos, James W Traweek Jr, James Warren Huff, Jason Douglas Wilson and Michael D Wortley.
View institutional ownership trends for Reata Pharmaceuticals
.

Which major investors are selling Reata Pharmaceuticals stock?

RETA stock was sold by a variety of institutional investors in the last quarter, including Biondo Investment Advisors LLC, UBS Group AG, SG Americas Securities LLC, Integral Health Asset Management LLC, JPMorgan Chase & Co., Alliancebernstein L.P., New York State Common Retirement Fund, and Franklin Resources Inc.. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Elaine Castellanos, James Warren Huff, and Michael D Wortley.
View insider buying and selling activity for Reata Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Reata Pharmaceuticals stock?

RETA stock was acquired by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Tolleson Wealth Management Inc., BlackRock Inc., GAM Holding AG, Geode Capital Management LLC, BOKF NA, and WCM Investment Management LLC.
View insider buying and selling activity for Reata Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $78.26.

How much money does Reata Pharmaceuticals make?

Reata Pharmaceuticals has a market capitalization of $2.83 billion and generates $26.52 million in revenue each year. The company earns $-290,170,000.00 in net income (profit) each year or ($9.54) on an earnings per share basis.

How many employees does Reata Pharmaceuticals have?

Reata Pharmaceuticals employs 261 workers across the globe.

What is Reata Pharmaceuticals' official website?

The official website for Reata Pharmaceuticals is www.reatapharma.com.

Where are Reata Pharmaceuticals' headquarters?

Reata Pharmaceuticals is headquartered at 5320 LEGACY DRIVE, PLANO TX, 75024.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The company can be reached via phone at 972-865-2219 or via email at [email protected]


This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.